


03-14-05

FFW
1642

CASE 4-20251C



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 372932 897 U.S.
Express Mail Label Number

3-11-05
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1642

TAYLOR ET AL.

APPLICATION NO: 10/001,755

FILED: OCTOBER 24, 2001

FOR: LIPOSOMAL INTERFERON HYBRID COMPOSITION

MAIL STOP: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Notice of Non-Compliant Amendment mailed February 11, 2005, having a period for response set to expire March 11, 2005, Applicants respectfully request the following amendment to be entered and the claims considered in light thereof. As the amendment is being filed within the time set for response, Applicants believe no additional fees are required. However, the Examiner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis Corporation for any fees required under 37 C.F.R. §1.17(a).

Amendments to the claims, including a listing of all claims present in the application in compliance with 37 C.F.R. §1.121, begins on page 2.

Remarks being on page 4.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3356
Date: MARCH 11, 2005

Regina Bautista
Regina Bautista
Attorney for Applicants
Reg. No. 46,280